Perigon Wealth Management LLC lowered its position in Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 9.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,226 shares of the medical research company’s stock after selling 340 shares during the period. Perigon Wealth Management LLC’s holdings in Edwards Lifesciences were worth $267,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of EW. Marshall Wace LLP lifted its position in Edwards Lifesciences by 167.5% during the third quarter. Marshall Wace LLP now owns 3,512,312 shares of the medical research company’s stock valued at $290,225,000 after purchasing an additional 2,199,410 shares in the last quarter. FMR LLC lifted its position in Edwards Lifesciences by 16.3% during the second quarter. FMR LLC now owns 8,861,392 shares of the medical research company’s stock valued at $842,630,000 after purchasing an additional 1,244,420 shares in the last quarter. Artisan Partners Limited Partnership purchased a new position in Edwards Lifesciences during the third quarter valued at $78,726,000. Voya Investment Management LLC lifted its position in Edwards Lifesciences by 305.3% during the second quarter. Voya Investment Management LLC now owns 1,218,590 shares of the medical research company’s stock valued at $115,875,000 after purchasing an additional 917,906 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in Edwards Lifesciences by 19.0% during the second quarter. Massachusetts Financial Services Co. MA now owns 5,381,049 shares of the medical research company’s stock valued at $511,685,000 after purchasing an additional 860,313 shares in the last quarter. Institutional investors own 80.35% of the company’s stock.
Insiders Place Their Bets
In other Edwards Lifesciences news, VP Daveen Chopra sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $78.00, for a total transaction of $312,000.00. Following the sale, the vice president now directly owns 18,911 shares of the company’s stock, valued at $1,475,058. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, VP Daveen Chopra sold 4,000 shares of the business’s stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $78.00, for a total transaction of $312,000.00. Following the completion of the transaction, the vice president now owns 18,911 shares in the company, valued at approximately $1,475,058. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael A. Mussallem sold 19,875 shares of the business’s stock in a transaction on Friday, January 13th. The shares were sold at an average price of $78.09, for a total value of $1,552,038.75. Following the transaction, the chief executive officer now owns 157,353 shares of the company’s stock, valued at approximately $12,287,695.77. The disclosure for this sale can be found here. Insiders have sold 101,821 shares of company stock valued at $7,902,704 over the last ninety days. 1.29% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
Edwards Lifesciences Trading Down 1.4 %
Shares of NYSE EW opened at $80.74 on Friday. The business’s 50 day moving average is $78.35 and its two-hundred day moving average is $79.39. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.03 and a quick ratio of 2.17. Edwards Lifesciences Co. has a 1-year low of $67.13 and a 1-year high of $131.10. The stock has a market capitalization of $48.94 billion, a P/E ratio of 33.09, a PEG ratio of 4.63 and a beta of 1.01.
Edwards Lifesciences (NYSE:EW – Get Rating) last issued its quarterly earnings data on Tuesday, January 31st. The medical research company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.03. Edwards Lifesciences had a return on equity of 26.05% and a net margin of 28.27%. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.33 billion. During the same period in the previous year, the firm posted $0.51 earnings per share. The firm’s revenue for the quarter was up 1.5% on a year-over-year basis. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.52 EPS for the current year.
Edwards Lifesciences Profile
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.
- Get a free copy of the StockNews.com research report on Edwards Lifesciences (EW)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW – Get Rating).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.